These observations indicate that the ability of statins in increasing T2DM is not due to off-target effects of the drug but rather to side effects of its effective blockage of HMG-CoA reductase; therefore, lacking downstream products of the mevalonate pathway must be responsible for the observed effects. Here, HMGCR is linked to type 2 diabetes mellitus.